Skip to content

EV / EBITDA at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
12.8×-1.3×
Astrana Health logo
Astrana HealthASTH
13.8×-0.8×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
19×+3.3×
Corvel logo
CorvelCRVL
14.8×-22.5×
LifeStance Health Group logo
LifeStance Health GroupLFST
27.4×-33.4×
CVS Health logo
CVS HealthCVS
9.2×+2.7×

Other financials

Income statement

See full
Revenue$603.8M+25.8%
Operating income$7.4M+42.2%
Net income$3.1M-27.4%
EPS (diluted)$0.02-33.3%

Balance sheet

See full
Cash & equivalents$419.5M-10.6%
Total debt$9.0M+66.0%
Total equity$753.1M+14.2%
Total assets$1.4B+19.8%

Cash flow

See full
Operating cash flow-$49.5M-106%
CapEx$23.0K+53.3%
Free cash flow$64.1M+120%

Valuation

See full
Market cap$2.99B-6.0%
Enterprise value$2.58B-4.8%
P/E137.5×-66.2×
P/S1.3×-0.4×

Profitability

See full
Operating margin1.6%+0.4pp
Net margin1%+0.1pp
FCF margin4.9%+1.4pp

Returns & leverage

See full
Return on equity3.1%+0.6pp
Debt / equity0.0×
Current ratio1.6×-0.3×

Where this comes from

Calculated from Privia Health Group, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Privia Health Group, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Privia Health Group, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Privia Health Group, Inc.'s EV / EBITDA?
Privia Health Group, Inc. (PRVA) reported EV / EBITDA of 44.7× in Q1 2026.
How has Privia Health Group, Inc.'s EV / EBITDA changed year-over-year?
Privia Health Group, Inc.'s EV / EBITDA decreased by 42.7% year-over-year, from 78× to 44.7×.
What is the long-term trend for Privia Health Group, Inc.'s EV / EBITDA?
Over 2 years (2023 to 2025), Privia Health Group, Inc.'s EV / EBITDA has grown at a -19.7% compound annual growth rate (CAGR), from 86× to 55.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.